Barrington Research raised DENTSPLY SIRONA Inc. XRAY price target from $20 to $21. Barrington Research analyst Michael ...

Intellia Therapeutics reported further progress with two treatments that are now ensconced in Phase III of testing. Click ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) just released its latest quarterly results and things are looking bullish. Revenues of US$17m beat estimates by a substantial 39% margin. Unfortunately, ...

Discover Q1 2025 earnings insights from Intellia Therapeutics (NTLA): Phase 3 progress, RMAT milestones, financial outlook, and competitive gene editing edge.

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos” or the "Company”), today announced its 2025 first quarter business ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of ...

Analysts expect Intellia Therapeutics to report an earnings per share (EPS) of $-1.27. Anticipation surrounds Intellia ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...